Human Immunoglobulin E specific for Ligustrum vulgare pollen allergens (sIgE (Ligustrum vulgare))

Human IgE antibodies specific for Ligustrum vulgare (common privet) pollen allergens are the key mediators of type I hypersensitivity reactions in individuals sensitized to this plant (PMID: 15110115). These antibodies primarily recognize Lig v 1, a major allergen belonging to the Ole e 1-like protein family, which is highly cross-reactive with allergens from other Oleaceae species like olive and ash (Allergen.org). When privet pollen is inhaled, these specific IgE molecules, bound to high-affinity receptors (FcεRI) on mast cells and basophils, become cross-linked by the allergen, triggering the immediate release of inflammatory mediators such as histamine and leukotrienes (StatPearls: Type I Hypersensitivity). This physiological cascade results in the clinical manifestations of seasonal allergic rhinitis, conjunctivitis, and potentially exacerbates asthma. Therapeutic interventions include the use of anti-IgE monoclonal antibodies like omalizumab to reduce overall IgE levels or allergen-specific immunotherapy (AIT) to modify the underlying immune response and induce long-term tolerance to Ligustrum vulgare pollen (PMID: 28024496).

Other names

Anti-privet IgELigustrum vulgare-specific IgELig v 1-specific IgEPrivet pollen-specific IgEAnti-Ligustrum vulgare IgE

Omalizumab binds to the Cε3 domain of the IgE molecule, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (FDA: Xolair Label). Allergen immunotherapy (AIT) works by gradually increasing exposure to the allergen to induce regulatory T cells and IgG4 blocking antibodies, shifting the immune response away from IgE-mediated hypersensitivity (PMID: 28024496).